Event-free survival as a predictor of overall survival and recurrence burden of patients with non –small cell lung cancer receiving neoadjuvant therapy
This study aims to examine the correlation between real-world event-free survival and overall survival and to assess the clinical and economic burden associated with disease recurrence among patients with resected stage II to III non –small cell lung cancer who received neoadjuvant therapy in the United States.
Source: The Journal of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Jessica Donington, Xiaohan Hu, Su Zhang, Yan Song, Ashwini Arunachalam, Diana Chirovsky, Chi Gao, Ari Lerner, Anya Jiang, James Signorovitch, Ayman Samkari Tags: Thoracic Source Type: research
More News: Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Clinical Trials | Heart | Lung Cancer | Neoadjuvant Therapy | Study | USA Health